FOLH1 and neoplasm: Therefore, although a homogenous therapy protocol which was composed of 3 cycles of highly standardized PSMA-RLT every 4 weeks was implied for the treatment of all mCRPC patients studied, heterogeneity of the treated patients with respect to their tumor burden and prior treatments to PSMA-RLT might limit the conclusions of the study.